Introduction
============

At present, colorectal cancer (CRC) is the third most common malignancy in males and the second in females worldwide ([@b1-ol-0-0-11125],[@b2-ol-0-0-11125]). Due to the high mortality rate, primarily as a result of occult or clinically overt metastases present at the time of diagnosis, and increased understanding of the molecular mechanisms underlying the malignant transformation of normal colorectal epithelial cells in the progression of adenoma to adenocarcinoma is required ([@b3-ol-0-0-11125]). Colorectal tumorigenesis is a complex process mediated by a number of genes and various signaling pathways, which ultimately results in the robust growth of transformed cells ([@b4-ol-0-0-11125],[@b5-ol-0-0-11125]). Despite notable progress in the current understanding of the mechanisms underlying this process, the aggressive nature and increased degree of metastasis of certain types of CRC requires further investigation. From a clinical perspective, improved understanding of these differences may aid the identification of prognostic biomarkers for CRC, consequently facilitating the personalized management of CRC to improve the prognosis of patients with this disease.

Bone morphogenetic proteins (BMPs) are members of the transforming growth factor-β (TGF-β) family, which are multi-functional cytokines ([@b6-ol-0-0-11125]). BMPs are divided into several subgroups, including the BMP-2/4, BMP-5/6/7/8 and BMP-9/10 groups, and the growth differentiation factor (GDF)-5/6/7 group, depending on their structural similarities and ability to bind certain type I receptors ([@b7-ol-0-0-11125]). Of note, 20 BMPs have been reported to possess a number of functions that regulate different physiological processes, including cellular proliferation, differentiation, migration and apoptosis ([@b8-ol-0-0-11125],[@b9-ol-0-0-11125]). BMP-9, also known as GDF-2, is a potent BMP member of the TGF-β family ([@b10-ol-0-0-11125]). Previous studies have demonstrated that BMP-9 acts as a multifunctional mediator in numerous biological processes, including the regulation of cell proliferation, differentiation, adhesion, migration and apoptosis ([@b11-ol-0-0-11125]--[@b13-ol-0-0-11125]). These processes are involved in bone morphogenesis, hepatic reticuloendothelial system function, neuronal differentiation, hematopoiesis, angiogenesis, and iron and glucose homeostasis ([@b10-ol-0-0-11125],[@b14-ol-0-0-11125]--[@b19-ol-0-0-11125]).

Accumulating evidence has demonstrated that BMP-9 is involved in tumorigenesis, and its expression varies according to tumor types. For example, compared with normal thyroid tissues, BMP-9 expression in thyroid tumors is increased ([@b20-ol-0-0-11125]). In addition, \~25% of ovarian cancers exhibit upregulated BMP-9, which has been associated with the tumorigenesis and progression of the disease ([@b21-ol-0-0-11125]). BMP-9 promotes the growth of hepatocellular carcinoma cells, but not that of immortalized human hepatocytes ([@b22-ol-0-0-11125]). Furthermore, BMP-9 enhances the invasiveness of hepatocellular carcinoma cells by inducing the epithelial-to-mesenchymal transition ([@b23-ol-0-0-11125]). Conversely, BMP-9 was demonstrated to act as an apoptotic regulator, suppressing tumor growth in prostate cancer and myeloma ([@b24-ol-0-0-11125],[@b25-ol-0-0-11125]). BMP-9 inhibits the proliferation, invasion and metastasis of breast cancer cells ([@b26-ol-0-0-11125]--[@b28-ol-0-0-11125]).

Due to its complex function, the ambiguous roles of BMP-9 as a tumor-promoting and tumor-suppressive factor require further investigation. Furthermore, the role of BMP-9 in colorectal tumorigenesis remains to be elucidated. The present study aimed to evaluate the prognostic value of BMP-9 expression in colorectal carcinoma, and to determine the association between the clinicopathological parameters of CRC and the prognostic potential of BMP-9 in patients with this disease.

Materials and methods
=====================

### Ethics statement

The present study was performed in accordance with the Declaration of Helsinki and approved by the Ethics Committee of The First Affiliated Hospital of Jinzhou Medical University. The Ethics Committee waived the need for written informed consent from the patients due to the retrospective nature of the present study. Each tissue sample and respective clinical data was anonymized and no additional patient intervention was performed.

### Clinical samples

A total of 65 patients with pathologically confirmed colorectal adenocarcinoma and a history of adenoma were enrolled in the present study; patients were surgically treated in The First Affiliated Hospital of Jinzhou Medical University (Jinzhou, China) between April 2012 and December 2014. The mean age of the 56 patients was 65 years (range, 47--84 years), and there were 47 men and 18 women. The inclusion criteria were as follows: i) Pathologically diagnosed with colorectal adenocarcinoma and a history of adenoma; ii) no previous neoadjuvant radiotherapy or chemotherapy treatment; and iii) no surgery for colorectal diseases. The exclusion criteria were as follows: i) Patients with other malignant tumors; ii) patients with severe organ dysfunction; and iii) patients with other types of colorectal diseases. The tissues obtained were fixed in 10% formaldehyde in PBS for 24 h at room temperature, and embedded in paraffin. For each patient, three paraffin-embedded tissue blocks were analyzed, comprising normal mucosa, adenoma and adenocarcinoma. All 195 tissue blocks were obtained from the Department of Pathology at The First Affiliated Hospital of Jinzhou Medical University. Pathological reports and the clinical history of patients were obtained from medical records. Follow-up information was available for 48 patients (73.85%). The patient demographics and the clinicopathological features of the specimens are summarized in [Table I](#tI-ol-0-0-11125){ref-type="table"}.

### Pathological examination and laboratory analysis

The Tumor-Node-Metastasis (TNM) staging and histological type of patient samples were primarily determined according to the 7th edition of the American Joint Committee\'s Cancer Staging Manual ([@b29-ol-0-0-11125],[@b30-ol-0-0-11125]). Dukes stages (A, B, C and D) were classified according to cancer invasion, lymph node metastasis and distant metastasis, referring to the Dukes staging of Colorectal Cancer (1984) ([@b31-ol-0-0-11125]).

In order to measure the levels of CEA and CA19-9, blood samples from 52 patients (80%) and 44 patients (67.69%), respectively, were obtained 2--3 days prior to surgery. Peripheral blood was centrifuged at 1,800 × g for 20 min at 4°C to obtain serum. The levels of these markers in the serum were measured using an i2000 automatic immunoluminescence analyzer (Abbott Laboratories). Serum levels of carcinoembryonic antigen (CEA) \>3.4 ng/ml and CA 19-9 \>27 U/ml were considered abnormal.

### Immunohistochemistry (IHC)

Formalin-fixed paraffin- embedded tissue blocks from the 65 patients, including colorectal mucosa, adenoma and adenocarcinoma specimens, were cut into 4 µm-thick sections and affixed to glass slides. Sections were deparaffinized in xylene, rehydrated via a descending alcohol series in double distilled water (including 100, 80, 70, 50 and 30% alcohol) for 2 min per concentration, and then rinsed in distilled water at room temperature. The antigen retrieval process performed was specific to each marker. For BMP-9, the slides were immersed in citrate buffer (10 mmol/l citric acid and sodium citrate; pH 6.0) and heated in a pressure cooker for 10 min at 100°C. In the case of Ki-67, the slides were boiled in citrate buffer (10 mmol/l citric acid and sodium citrate; pH of 6.0) at 100°C in a microwave oven for 20 min. The slides were allowed to cool at room temperature for 60 min and were then blocked with 1% bovine serum albumin in TBS (Sigma-Aldrich; Merck KGaA) for 60 min at room temperature. Staining was performed in a humidified chamber overnight at 4°C using the following antibodies (both from Abcam): Anti-BMP-9 (1:100; cat. no. ab35088) and anti-Ki-67 (1:250; cat. no. ab15580). Following incubation with primary antibodies, endogenous peroxidase activity was blocked by incubating the slides with 3% hydrogen peroxide for 10 min at room temperature. The sections were subsequently stained using the two-step plus^®^ Poly-HRP Anti-Mouse/Rabbit IgG Detection System (cat. no. PV-9000; OriGene Technologies, Inc) for 20 min at room temperature. BMP-9 and Ki-67 expression was visualized via staining with 3,3′-diaminobenzidine (Sigma-Aldrich; Merck KGaA) for 5 and 2 min at room temperature, respectively. The nuclei were counterstained with hematoxylin for 8 min (Sigma-Aldrich; Merck KGaA) at room temperature. The slides were dehydrated via an alcohol gradient, including 100, 70, 50 and 30% alcohol, in double distilled water for 1 min each time and then immersed in xylene. Subsequently, the slides were fixed with Histomount mounting medium (cat. no. HS-103-100ML; AGTC Bioproducts Ltd.)

### Evaluation of staining

All immunostained sections were evaluated semi-quantitatively under an Olympus BX40 light microscope (Olympus Corporation; magnification, ×400) by two investigators from the The First Affiliated Hospital of Jinzhou Medical University (Jinzhou, Liaoning) who were blinded to the clinicopathological data. In the case of discrepancies between the evaluators, a consensus was reached after obtaining a third and final opinion from the director of the Department of Pathology at The First Affiliated Hospital of Jinzhou Medical University. BMP-9 expression was calculated as the product of the relative score, reflecting the percentage of positively stained cells (0, \<5%; 1, 5--25%; 2, 25--50%; 3, 50--75%; and 4, \>75%), and the intensity of the staining (0, negative; 1, weak; 2, moderate; and 3, strong). The final BMP-9 expression score ranged from 0--12, and was subsequently classified into 4 levels: '−' for negative (0), '+' for mild ([@b1-ol-0-0-11125]--[@b3-ol-0-0-11125]), '++' for moderate ([@b4-ol-0-0-11125]--[@b7-ol-0-0-11125]) and '+++' for strong ([@b8-ol-0-0-11125]--[@b12-ol-0-0-11125]). For the assessment of Ki-67 expression, cells with positive nuclear staining were counted and the percentage of positively stained cells was calculated as aforementioned. The staining was assessed as '−' (negative, \<5%), '+' (moderately positive, 5--25%), '++' (positive, 25--50%) and '+++' (strongly positive, \>50%).

### Bioinformatics analysis

To further analyze the role of BMP-9 in CRC, the expression of BMP-9 and the clinicopathological data of patients were extracted from The Cancer Genome Atlas (TCGA) (<https://cancergenome.nih.gov/>). Additionally, the Kurashina (GSE11417) ([@b32-ol-0-0-11125]) and Gaedcke (GSE20842) ([@b33-ol-0-0-11125]) dataset from the Oncomine database (<https://www.oncomine.org/>), which is a cancer microarray database and web-based data-mining platform for genome-wide expression analyses, was downloaded. The data employed were used to compare differences in BMP-9 expression at the mRNA level between healthy colorectal tissue and tumor tissues. In addition, the correlation between BMP-9 expression, and the clinicopathological and prognostic data of patients with CRC was determined. All data were log-transformed, median-centered per array and standard deviation-normalized to one per array.

### Statistical analysis

The expression of BMP-9 in colorectal tumorigenesis and the associations between the clinicopathological features and the status of BMP-9 expression were assessed via Spearman\'s rank correlation analysis. A Kaplan-Meier analysis was performed in order to estimate the 5-year overall survival (OS) rate for patients with CRC with low- or high- BMP-9 expression levels. These expression groups were defined according to the mean IHC score (2.17); IHC scores 0--2 were considered to indicate low-BMP-9 expression, while a score of ≥3 was recorded as high BMP-9 expression. Differences between groups were analyzed with a log-rank test. Significant factors from univariate analyses were included in the multivariate models. A Cox proportional hazards model was used to perform multivariate survival analyses in order to identify independent prognostic factors. For the bioinformatics analysis, the BMP-9 expression levels in different colorectal tissues were compared using a repeated measures ANOVA. The comparison of data from multiple groups against a single control group was performed using a Dunnett\'s post hoc test. The comparison of data from multiple groups against every other group was performed using a Tukey\'s multiple comparisons test. P\<0.05 was considered to indicate a statistically significant difference. All statistical analyses were conducted using SPSS software (version 20; IBM Corp.) and GraphPad Prism software (version 7.0; GraphPad Software Inc.).

Results
=======

### Expression of BMP-9 in CRC

In order to investigate the role of BMP-9 in colorectal tumorigenesis, the present study assessed BMP-9 expression in normal mucosa, adenoma and colorectal carcinoma samples using IHC staining. In normal colorectal mucosa, decreased BMP-9 expression was detected in the cell membrane and cytoplasm of colorectal mucosal cells; in the majority of cases (60/65, 92.31%), the protein was not present in the nucleus ([Fig. 1A](#f1-ol-0-0-11125){ref-type="fig"}). In colorectal adenoma tissues, BMP-9 was moderately expressed in the membrane and/or cytoplasm at a level similar to that in normal tissues. In addition, BMP-9 expression was undetectable in the nucleus in the majority of cases (62/65, 95.38%) ([Fig. 1B](#f1-ol-0-0-11125){ref-type="fig"}). On the contrary, in carcinoma tissues, BMP-9 was strongly expressed and predominantly observed in the membrane and/or cytoplasm of cancer cells, but was weakly expressed or undetectable in the nucleus ([Fig. 1C](#f1-ol-0-0-11125){ref-type="fig"}; [Table II](#tII-ol-0-0-11125){ref-type="table"}). The positive rates of BMP-9 expression in normal colorectal mucosa, adenoma and carcinoma tissues were 68, 91 and 95%, respectively ([Table II](#tII-ol-0-0-11125){ref-type="table"}). The expression levels of BMP-9 presented an upward trend in the aforementioned tissues, with mean values of 0.7, 1.8 and 2.2, respectively. The elevated BMP-9 expression levels of the three types of tissue were statistically significant (r^2^=0.615; P\<0.05). Furthermore, BMP-9 expression was significantly upregulated in carcinoma samples when compared with adenoma samples (r^2^=0.221; P\<0.05) ([Table II](#tII-ol-0-0-11125){ref-type="table"}). Similarly, significantly increased BMP-9 expression was observed in adenoma tissues compared with normal mucosa (r^2^=0.572; P\<0.05). In the TCGA and Gaedcke and Kurashina datasets, BMP-9 mRNA expression was significantly increased in CRC tissues compared with healthy tissues (P\<0.05; [Fig. 2A-C](#f2-ol-0-0-11125){ref-type="fig"}).

### Correlation between BMP-9 expression and tumor cell proliferation in human CRC

In order to examine the correlation between BMP-9 expression and cell proliferation, the expression of Ki-67 in the same sample set was evaluated by IHC. In normal mucosa, cells positive for nuclear Ki-67 were localized primarily at the bottom of the glands, whereas, in adenoma and carcinoma samples, such cells were distributed randomly ([Fig. 1D-F](#f1-ol-0-0-11125){ref-type="fig"}). The mean Ki-67 indices were significantly higher in adenoma and carcinoma compared with normal tissues (2.4, 2.9 and 1.4, respectively; r^2^=0.711; P\<0.001). Interestingly, the Ki-67 index increased with more advanced cancer stages (r^2^=0.50; P\<0.001 adenoma vs. carcinoma; [Table III](#tIII-ol-0-0-11125){ref-type="table"}). In addition, no correlation between BMP-9 and Ki-67 expression in CRC was observed (r^2^=−0.024; P\>0.05; [Table IV](#tIV-ol-0-0-11125){ref-type="table"}).

### Correlation between BMP-9 expression and the clinicopathological parameters of CRC

The expression of BMP-9 was significantly correlated with age (r^2^=−0.329; P=0.007), but not with other features, including sex, tumor location, gross tumor type, differentiation, histological type, WHO classification, blood vessel tumor emboli, TNM stage, and serum CEA and CA19-9 levels ([Table V](#tV-ol-0-0-11125){ref-type="table"}). In the Oncomine dataset, no significant association between BMP-9 mRNA and clinicopathological parameters was observed (P\>0.05). In TCGA dataset, BMP-9 mRNA expression was not associated with the TNM stage (P\>0.05; [Fig. 2F-I](#f2-ol-0-0-11125){ref-type="fig"}). In the Kurashina dataset, BMP-9 expression was not associated with the grade classifications and Dukes stages (P\>0.05; [Fig. 2D and E](#f2-ol-0-0-11125){ref-type="fig"}).

### Survival analysis

In the follow-up period of ≥3 years, the OS was 71%; 14 patients had succumbed, including 2 patients who underwent a secondary operation. Of these 2 patients, one had undergone a secondary operation for an intestinal fistula observed 1 month after the initial procedure. The patient subsequently succumbed due to infectious peritonitis and septic shock. For the other patient, a secondary operation was conducted due to tumor relapse, which was identified 3 months after the initial procedure. The patient succumbed due to tumor progression and multiple organ metastasis 16 months after the primary surgery. Distant metastases were observed in 3 other patients; in the liver (after 11 months), the brain (after 25 months) and the bones (after 38 months), respectively. In addition, locoregional relapse was observed in 2 patients after 14 and 26 months, respectively.

In order to assess the association between the expression levels of BMP-9 and OS in colorectal carcinoma, BMP-9 expression was categorized into low- and high-expression groups according to the mean of their IHC scores. A total of 32 patients (67%) had low BMP-9 expression levels, and 16 patients (33%) exhibited high BMP-9 expression. Low BMP-9 expression was significantly associated with improved OS; the mean survival time for such patients was 56.4 months with a 95% confidence interval (CI) of 50.8--62.0. On the contrary, high BMP-9 expression was associated with a mean survival time of 38.3 months with a 95% CI of 25.7--50.8, whjch was significantly lower than the low-expression group (P=0.009; [Table VI](#tVI-ol-0-0-11125){ref-type="table"}; [Fig. 3](#f3-ol-0-0-11125){ref-type="fig"}).

In the univariate analyses, certain clinicopathological parameters, including tumor differentiation, WHO classification, blood vessel cancer embolus and TNM staging were significant predictors of a poor prognosis (P=0.035, 0.035, \<0.001 and 0.022, respectively; [Table VI](#tVI-ol-0-0-11125){ref-type="table"}). Sex, age, tumor location, gross tumor type, histological type, serum CEA and CA 19-9 levels were not associated with the prognosis of patients (all P\>0.05; [Table VI](#tVI-ol-0-0-11125){ref-type="table"}).

Furthermore, BMP-9 expression was independently associated with poor prognosis in CRC (P=0.044) as determined by multivariate analyses, which indicated the prognostic significance of BMP-9 expression in CRC \[hazard ratio (HR), 3.14; 95% CI, 1.03--9.57; [Table VII](#tVII-ol-0-0-11125){ref-type="table"}\].

Bioinformatics analysis using the available datasets confirmed the observations that patients with CRC and high BMP-9 mRNA expression exhibited decreased OS time compared with those with low expression ([Fig. 4A-L](#f4-ol-0-0-11125){ref-type="fig"}).

Discussion
==========

BMP-9 belongs to the TGF-β family and serves as a multifunctional mediator in numerous biological processes under physiological and pathophysiological conditions, particularly in tumorigenesis ([@b10-ol-0-0-11125]--[@b19-ol-0-0-11125]). The expression of BMP-9 and its tumorigenic and antitumorigenic roles notably varies according to the type of tumor ([@b22-ol-0-0-11125],[@b23-ol-0-0-11125],[@b25-ol-0-0-11125],[@b28-ol-0-0-11125]). To the best of our knowledge, the present study is the first to investigate the role of BMP-9 in the various stages of colorectal tumorigenesis, a process observed in the majority of types of colorectal tumor ([@b3-ol-0-0-11125],[@b34-ol-0-0-11125],[@b35-ol-0-0-11125]), by analyzing matched normal mucosa, adenoma and carcinoma samples. The present study demonstrated that the expression of BMP-9 sequentially increased in normal mucosa, adenoma and carcinoma. These results suggested that BMP-9 may be an important protumorigenic factor in the development of CRC. In addition, it was revealed that BMP-9 may serve as an independent prognostic factor for patients with CRC, and that high BMP-9 expression was significantly associated with poor prognosis and decreased survival rate.

BMP-9 was first detected in fetal mouse liver, and it can bind to activin receptor-like kinase 1, a TGF family type 1 receptor, to serve an important role in angiogenesis ([@b10-ol-0-0-11125],[@b19-ol-0-0-11125]). It is well known that angiogenesis is a critical process in tumorigenesis ([@b36-ol-0-0-11125]). Recently, Na *et al* ([@b20-ol-0-0-11125]) reported that BMP-9 was upregulated in papillary thyroid carcinoma compared with normal follicular cells (P\<0.001), regardless of bone formation. Similarly, Herrera *et al* ([@b21-ol-0-0-11125]) detected BMP-9 expression in epithelial ovarian cancer cells, but not in normal human ovarian surface epithelial cells. The results of the present study suggested an increase in BMP-9 expression with advancing stages of colorectal tumorigenesis. Conversely, Ren *et al* ([@b27-ol-0-0-11125]) revealed that BMP-9 may function as a tumor suppressor in breast cancer cells *in vitro* and *in vivo*. A similar role was also reported for BMP-9 in prostate cancer ([@b24-ol-0-0-11125],[@b37-ol-0-0-11125]), osteosarcoma ([@b38-ol-0-0-11125]) and myeloma ([@b25-ol-0-0-11125]). These discrepancies require further investigation; however, they indicate that the role of BMP-9 may be tissue- and tumor-specific.

BMP signaling has been investigated in the development of colorectal carcinogenesis ([@b39-ol-0-0-11125]--[@b41-ol-0-0-11125]). Although research has been performed following the detection of a germline mutation of bone morphogenetic protein receptor type 1A in patients with juvenile polyposis syndrome, the precise role of BMP signaling in CRC remains unclear ([@b42-ol-0-0-11125],[@b43-ol-0-0-11125]). BMP-2 and BMP-3 were determined to have growth-suppressive activities in colon cancer cells ([@b8-ol-0-0-11125],[@b44-ol-0-0-11125]). However, Yokoyama *et al* ([@b6-ol-0-0-11125]) reported that the expression levels of BMP-4 in human CRC cells and tissues were upregulated when compared with those in normal epithelium or adenoma, while inhibition of BMP-4 promoted the apoptosis of CRC cells *in vitro* and *in vivo*. These findings were consistent with the reports of the present study. Furthermore, Yuan *et al* ([@b45-ol-0-0-11125]) demonstrated that BMP-9 was essential for the antiproliferative effects of resveratrol on human colon cancer. Conversely, Lorente-Trigos *et al* ([@b46-ol-0-0-11125]) revealed that BMP signaling promoted the growth of primary human colon carcinomas *in vivo*. Whether the inconsistency in these reports is due to context differences or cross-talk involving other signaling pathways in colorectal tumorigenesis at different stages requires further investigation.

Notably, in the present study, the expression of BMP-9 gradually increased within the cytoplasm or/and membrane in tissues of advancing tumor stages, from normal colorectal mucosa to adenoma and carcinoma. This suggested a potential role of high cytoplasmic or membranous BMP-9 expression in colorectal tumorigenesis. Similarly, an increase of galectin 3 in the cytoplasm has been associated with the progression of CRC ([@b47-ol-0-0-11125]). Miyata *et al* ([@b48-ol-0-0-11125]) also observed a similar correlation between the enhanced expression of ELAV like RNA binding protein 1 in the cytoplasm, and the aggressiveness and poor prognosis of bladder cancer. However, due to the limitations of IHC staining in the present study, the correlation between the cytoplasmic expression of BMP-9 and poor prognosis in patients with CRC could not be assessed.

In order to evaluate the prognostic value of BMP-9 expression in patients with CRC, a Kaplan-Meier univariate survival analysis was performed in the present study, which revealed an association between high BMP-9 expression levels and poor prognosis in patients with this disease. When the Cox proportional hazards model was generated, high BMP-9 expression levels were determined to be an independent factor for predicting the unfavorable prognosis of patients with CRC. These results suggested that BMP-9 may be a prognostic marker for patients with this disease.

Numerous proteins or genes identified thus far have been used as prognostic biomarkers for various types of CRC ([@b49-ol-0-0-11125],[@b50-ol-0-0-11125]); however, improvements are required. Considering the results from the present study, BMP-9 may be a valuable addition to the clinical management of patients with CRC and could contribute to the improvement of treatment outcomes.

An increasing number of studies have focused on BMP-9 as a therapeutic target for the treatment of cancer, particularly tumor angiogenesis ([@b51-ol-0-0-11125],[@b52-ol-0-0-11125]). In light of the results from the present study, the development of a novel therapeutic strategy targeting BMP-9 in CRC is warranted.

The primary limitation of the present study was the evaluation of BMP-9 expression using IHC staining. The semi-quantitative nature of this analysis may have negatively influenced its statistical power. Therefore, reverse transcription-quantitative PCR should be performed in order to confirm the results of the present study, along with a more thorough correlation analysis. Furthermore, other limitations included the small sample size employed, and the lack recurrence-free and disease-free survival data.

The findings of the present study suggested that increased BMP-9 expression may serve an important role in promoting colorectal tumorigenesis by driving the transformation of colorectal normal mucosa to adenoma, and subsequent carcinoma. In addition, upregulated BMP-9 levels may be an independent predictor of poor prognosis for patients with CRC. Thus, modulating BMP-9 activity may be considered as a novel therapeutic strategy in the treatment of CRC; however, further investigation is warranted to elucidate the mechanism underlying the protumorigenic effects of BMP-9 in the disease.
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![Bone morphogenetic protein-9 expression in (A) normal colorectal mucosa; (B) colorectal adenoma; and (C) carcinoma. Ki-67 expression in (D) normal colorectal mucosa, (E) colorectal adenoma and (F) carcinoma in a series of tissue samples obtained from the same patient (magnification, ×400).](ol-19-01-0271-g00){#f1-ol-0-0-11125}

![Association between the clinicopathological parameters of CRC and BMP-9 expression. TCGA (mRNA), Kurashina (DNA) and Gaedcke (mRNA) datasets were utilized for the bioinformatics analysis to investigate BMP-9 expression in colorectal carcinogenesis. (A) Increased BMP-9 expression was detected in CRC tissue compared with normal colorectal mucosa in the Kurashina dataset. \*P\<0.001, \*\*P\<0.05, \*\*\*P\<0.01 vs. colon mucinous adenocarcinoma. (B) Analysis of the Gaedcke dataset indicated that BMP-9 expression in rectal adenocarcinoma was increased compared with normal rectal mucosa (\*P\<0.001). (C) BMP-9 expression was significantly upregulated in CRC tissue compared with normal colorectal mucosa in the TCGA dataset. \*P\<0.001, \*\*P\<0.01, \*\*\*P\<0.05 vs. colon and rectum. From the Kurashina dataset, BMP-9 expression was determined to not be associated with (D) grade classifications and (E) Dukes staging of CRC (P\>0.05). (F-I) Analysis of the dataset of TCGA revealed that BMP-9 mRNA expression were not associated with the TNM stages of CRC (P\>0.05). BMP-9, bone morphogenetic protein-9; CRC, colorectal cancer; TCGA, The Cancer Genome Atlas; T, Tumor; N, Node; M, metastasis.](ol-19-01-0271-g01){#f2-ol-0-0-11125}

![Overall survival rate of patients with colorectal cancer with varying expression levels of BMP-9. Red and green indicate high (IHC scores: \>2) and low expression (IHC scores: ≤2), respectively. HR, hazard ratio.](ol-19-01-0271-g02){#f3-ol-0-0-11125}

![Prognostic value of BMP-9 expression in CRC. The TCGA (mRNA) and Kurashina (DNA) datasets were used to analyze the prognostic value of BMP-9 in colorectal carcinogenesis. Analysis of The Cancer Genome Atlas and Kurashina datasets revealed that BMP-9 mRNA expression was not associated with the overall survival rates of patients with CRC in (A) Kurashina and (F) TCGA datasets, regardless of subsequent analysis that stratified patients into the following subgroups: (B) Grade 1; (C) grade 2; (D) Dukes stage B; (E) Dukes stage C; (G) stage II; (H) T3; (I) N0; (J) N2; (K) M0; and (L) M1. BMP-9, bone morphogenetic protein-9; CRC, colorectal cancer; HR, hazard ratio; TCGA, The Cancer Genome Atlas; T, tumor; N, node; M, metastasis.](ol-19-01-0271-g03){#f4-ol-0-0-11125}

###### 

Clinical and demographic characteristics of patients enrolled in the present study.

  Characteristics              n (%)
  ---------------------------- --------------
  Sex                          
    Male                       47/65 (72.3)
    Female                     18/65 (27.7)
  Age, years                   
    ≤55                        11/65 (16.9)
    \>55                       54/65 (83.1)
  Tumor site                   
    Rectum                     39/65 (60.0)
    Left-side colon            17/65(26.2)
    Right-side colon           9/65 (13.8)
  Gross tumor type             
    Ulcerative                 49/65 (75.4)
    Elevated                   16/65 (24.6)
  Tumor differentiation        
    Poor                       6/65 (9.2)
    Moderate                   54/65 (83.1)
    High                       5/65 (7.7)
  Tumor histological type      
    Tubular papillary          16/65 (24.6)
    Tubular                    44/65 (67.7)
    Mucinous                   5/65 (7.7)
  Tumor WHO classification     
    Low                        53/65 (81.5)
    High                       12/65 (18.5)
  Blood vessel tumor embolus   
    Positive                   7/65 (10.8)
    Negative                   58/65 (89.2)
  TNM stage                    
    I--II                      46/65 (70.8)
    III--IV                    19/65 (29.2)
  Serum CEA levels             
    High                       22/52 (42.3)
    Normal                     30/52 (57.7)
  Serum CA19-9 levels          
    High                       9/44 (20.5)
    Normal                     35/44 (79.5)
  Adenomas site                
    Left-side colon            14/65 (21.5)
    Right-side colon           11/65 (16.9)
    Rectum                     40/65 (61.6)
  Number of adenomas           
    Single                     56/65 (86.2)
    Multiple                   9/65 (13.8)
  Adenomas histological type   
    Tubular                    41/65 (63.1)
    Tubulovillous              24/65 (36.9)
  Adenoma dysplasia            
    Mild                       29/65 (44.6)
    Moderate                   27/65 (41.5)
    Severe                     9/65 (13.9)

TNM, Tumor-Node-Metastasis; CEA, carcinoembryonic antigen, CA19-9, carbohydrate antigen 19-9; WHO, World Health Organization.

###### 

BMP-9 expression in colorectal carcinoma, adenoma and normal colorectal mucosa.

                             BMP-9 expression, n (%)                                 
  -------------------------- ------------------------- --------- --------- --------- ----
  Normal colorectal mucosa   21 (32)                   42 (65)   2 (3)     0 (0)     68
  Colorectal adenoma         6 (9)                     20 (31)   22 (34)   17 (26)   91
  Colorectal carcinoma       3 (5)                     8 (12)    29 (45)   25 (38)   95

BMP-9, bone morphogenetic protein-9; PR, positive rate.

###### 

Ki-67 expression in colorectal carcinoma, adenoma and normal colorectal mucosa.

                             Ki-67 expression, n (%)                                               
  -------------------------- ------------------------- --------- --------- --------- ----- ------- ----------
  Normal colorectal mucosa   12 (18)                   24 (37)   22 (34)   7 (11)    82    0.711   P\<0.001
  Colorectal adenoma         0 (0)                     6 (9)     27 (42)   32 (49)   100           
  Colorectal carcinoma       1 (2)                     0 (0)     2 (3)     62 (95)   98            

PR, positive rate; r^2^, Spearman\'s Rank Correlation Coefficient.

###### 

Correlation between BMP-9 and Ki-67 expression in colorectal cancer.

                                   BMP-9 expression, n                          
  --------------------- ----- ---- --------------------- --- ---- ---- -------- -------
  Ki-67 expression, n   --    1    0                     0   1    0    −0.024   0.852
                        \+    0    0                     0   0    0             
                        ++    2    0                     0   1    1             
                        +++   62   3                     8   27   24            

BMP-9, bone morphogenetic protein-9; r^2^, Spearman\'s Coefficient of Rank Correlation.

###### 

Association between BMP-9 expression and the clinicopathological characteristics of patients with colorectal cancer.

                                   BMP-9 expression, n                          
  --------------------------- ---- --------------------- --- ---- ---- -------- -------
  Sex                                                                  −0.146   0.246
    Male                      47   3                     5   18   21            
    Female                    18   0                     3   11   4             
  Age, years                                                           −0.329   0.007
    ≤55                       11   0                     0   3    8             
    \>55                      54   3                     8   26   17            
  Site                                                                 0.048    0.703
    Rectum                    39   2                     6   18   13            
    Left-side colon           17   1                     1   7    8             
    Right-side colon          9    0                     1   4    4             
  Tumor gross type                                                     −0.067   0.596
    Ulcerative type           49   3                     5   21   20            
    Elevated type             16   0                     3   8    5             
  Differentiation                                                      −0.175   0.164
    Poor                      6    0                     0   3    3             
    Moderate                  54   2                     6   26   20            
    High                      5    1                     2   0    2             
  Histological type                                                    −0.058   0.649
    Tubular papillary         16   1                     0   10   5             
    Tubular                   44   1                     6   19   18            
    Mucinous                  5    1                     2   0    2             
  WHO classification                                                   −0.023   0.856
    Low                       53   2                     6   25   20            
    High                      12   1                     2   4    5             
  Blood vessel tumor emboli                                            −0.039   0.760
    Positive                  7    0                     1   3    3             
    Negative                  58   3                     7   26   22            
  TNM stage                                                            −0.010   0.938
    I--II                     46   2                     6   20   18            
    III--IV                   19   1                     2   9    7             
  Serum CEA levels                                                     −0.035   0.805
    High                      22   2                     3   7    10            
    Normal                    30   1                     3   16   10            
  Serum CA19-9 levels                                                  −0.110   0.476
    High                      9    0                     1   4    4             
    Normal                    35   2                     5   16   12            

BMP-9, bone morphogenetic protein-9; WHO, World Health Organization; TNM, Tumor-Node-Metastasis; CEA, carcinoembryonic antigen, CA19-9, carbohydrate antigen 19-9; r^2^, Spearman\'s Coefficient of Rank Correlation.

###### 

Univariate analysis for BMP-9 expression and clinicopathological variables in patients with colorectal cancer.

  Characteristics              Number of patients, n   Mean survival time, months   95% CI           P-value
  ---------------------------- ----------------------- ---------------------------- ---------------- ---------
  BMP-9 expression                                     50.485                       44.330--56.640   0.009
    Low                        32                      56.420                       50.838--62.001   
    High                       16                      38.250                       25.675--50.825   
  Sex                                                  50.485                       44.330--56.640   0.682
    Male                       33                      48.821                       40.753--56.888   
    Female                     15                      50.023                       43.343--56.721   
  Age, years                                           50.485                       44.330--56.640   0.404
    ≤55                        7                       43.143                       25.195--61.091   
    \>55                       41                      50.929                       44.598--57.260   
  Tumor site                                           50.485                       44.330--56.640   0.066
    Rectum                     28                      53.415                       46.560--60.270   
    Left-side colon            14                      47.071                       36.059--58.083   
    Right-side colon           6                       31.833                       13.128--50.539   
  Gross tumor type                                     50.485                       44.330--56.640   0.083
    Ulcerative type            37                      46.533                       39.125--53.941   
    Elevated type              11                      61.909                       58.002--65.817   
  Differentiation                                      50.485                       44.330--56.640   0.035
    Poor                       5                       30.000                       11.555--48.445   
    Moderate                   38                      53.690                       47.209--60.171   
    High                       5                       41.400                       26.588--56.212   
  Histological type                                    50.485                       44.330--56.640   0.353
    Tubular papillary          11                      52.176                       42.042--62.291   
    Tubular                    32                      51.031                       43.061--59.001   
    Mucinous                   5                       41.400                       26.588--56.212   
  WHO classification                                   50.485                       44.330--56.640   0.035
    Low                        37                      53.346                       46.691--60.002   
    High                       11                      39.818                       26.680--52.956   
  Blood vessel tumor embolus                           50.485                       44.330--56.640   \<0.001
    Positive                   43                      54.003                       48.395--59.611   
    Negative                   5                       16.000                       4.046--27.954    
  TNM stage                                            50.485                       44.330--56.640   0.022
    I--II                      32                      54.088                       47.489--60.686   
    III--IV                    16                      41.193                       29.813--52.572   
  Serum CEA levels                                     49.350                       42.681--56.018   0.185
    High                       21                      54.420                       44.365--56.475   
    Normal                     18                      44.222                       32.885--55.559   
  Serum CA19-9 levels                                  45.344                       38.817--51.871   0.073
    High                       26                      48.793                       42.597--54.990   
    Normal                     7                       32.429                       15.235--49.622   

BMP-9, bone morphogenetic protein-9; CI, confidence interval; WHO, World Health Organization; TNM, Tumor-Node-Metastasis; CEA, carcinoembryonic antigen; CA19-9, carbohydrate antigen 19-9.

###### 

Multivariate Cox regression analysis for overall survival in patients with colorectal cancer.

  Characteristics              HR      95% CI          P-value
  ---------------------------- ------- --------------- ---------
  BMP-9 expression             3.143   1.032--9.571    0.044
  Differentiation              1.021   0.435--2.395    0.962
  WHO classification           1.044   0.232--4.705    0.955
  Blood vessel tumor embolus   5.142   0.866--30.315   0.072
  TNM stage                    1.896   0.506--7.103    0.343

HR, hazard ratio; CI, confidence interval; BMP-9, bone morphogenetic protein-9; WHO, World Health Organization.
